GlassScriptPhysician profile
Neeraj Desai
NPI 1871514638
$47,716.45
in general payments reported to CMS, 2019-2025
46 companies · $6,220 in 2025
The $6,220 reported for 2025 was more than what 90% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $776 · 2021: $7,402 · 2022: $11K · 2023: $7,359 · 2024: $5,092 · 2025: $6,220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,000 · Food and Beverage: $4,356 · Consulting Fee: $4,028 · Travel and Lodging: $2,255 · Education: $32.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,000.00 |
| Food and Beverage | $4,355.97 |
| Consulting Fee | $4,027.50 |
| Travel and Lodging | $2,254.66 |
| Education | $32.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $17,207.83 | 2019-2025 | Da Vinci Surgical System, Da Vinci Sp |
| Astrazeneca Pharmaceuticals LP | $10,944.06 | 2019-2024 | Imfinzi, Tagrisso, Airsupra |
| Boston Scientific Corporation | $9,348.70 | 2019-2024 | |
| Steelhead Surgical INC | $2,400.00 | 2022 | |
| Glaxosmithkline, LLC. | $2,273.96 | 2019-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Pulmonx Corporation | $1,153.83 | 2019-2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Boehringer Ingelheim Pharmaceuticals, INC. | $890.11 | 2019-2024 | Spiriva Respimat, Stiolto Respimat, Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $321.21 | 2022-2024 | Glassia |
| Pfizer INC. | $309.93 | 2022-2024 | |
| Genzyme Corporation | $260.01 | 2023-2025 | |
| Erbe USA INC | $241.68 | 2019-2023 | Erve |
| Harmony Biosciences LLC | $239.33 | 2020-2023 | Wakix |
| Grifols USA, LLC | $233.67 | 2019-2023 | Prolastin-C Liquid |
| Electromed, INC. | $217.52 | 2019-2024 | Smartvest |
| Genentech USA, INC. | $215.96 | 2019-2025 | Tecentriq, Tecentriq Hybreza, Alecensa |
Show all 45 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neeraj Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.